硼替佐米治疗儿童复发/难治性B系急性淋巴细胞白血病研究进展  

Progress of bortezomib in children with relapsed/refractory B-cell acute lymphoblastic leukemia

作　　者：王玉姣 赵睿博 郝良纯[1] Wang Yujiao;Zhao Ruibo;Hao Liangchun(Department of Pediatric Hematology,Shengjing Hospital of China Medical University,Shenyang 110004,China;The Second Clinical College of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院小儿血液科,沈阳110004 [2]中国医科大学第二临床学院,沈阳110004

出　　处：《国际儿科学杂志》2024年第1期29-33,共5页International Journal of Pediatrics

摘　　要：急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是儿童最常见的恶性肿瘤,通常预后良好,但儿童复发/难治性ALL的预后较差,大剂量再诱导化疗和造血干细胞移植成为这类患者的替代治疗。硼替佐米作为初代蛋白酶体抑制剂,获批用于治疗多发性骨髓瘤和套细胞淋巴瘤。近年来一些临床研究证实,硼替佐米可以与多种化疗药物联合应用,安全且有效地治疗儿童复发/难治性ALL,提高此类患者的完全缓解率和生存率。该文综述硼替佐米对ALL的作用机制及硼替佐米联合化疗在儿童复发/难治性ALL中的临床研究进展和安全性。Acute lymphoblastic leukemia(ALL)is the most common pediatric cancer and has good outcome.However,the prognosis of relapsed/refractory ALL in children is poor.Intensive reinduction chemotherapy and hematopoietic stem cell transplantation have become alternative treatments.Bortezomib,as the primary generation proteasome inhibitor,has been approved for the treatment of multiple myeloma and mantle cell lymphoma.In recent years,several clinical studies have confirmed promising responses and well tolerated of bortezomib combined with various chemotherapeutic drugs in treating children with relapsed/refractory ALL,to improve the complete remission rate and survival rate.This article reviews the mechanisms of bortezomib in ALL and the clinical study progress and safety of bortezomib combined with chemotherapy in children with relapsed/refractory ALL.

关 键 词：儿童 急性淋巴细胞白血病 硼替佐米 

分 类 号：R733.71[医药卫生—肿瘤]